Clinical Drug Investigation

, Volume 32, Issue 10, pp 673–684

Bioequivalence Evaluation of a Folate-Supplemented Oral Contraceptive Containing Ethinylestradiol/Drospirenone/Levomefolate Calcium versus Ethinylestradiol/Drospirenone and Levomefolate Calcium Alone

  • Herbert Wiesinger
  • Urte Eydeler
  • Frank Richard
  • Dietmar Trummer
  • Hartmut Blode
  • Beate Rohde
  • Konstanze Diefenbach
Original Research Article

DOI: 10.1007/BF03261921

Cite this article as:
Wiesinger, H., Eydeler, U., Richard, F. et al. Clin Drug Investig (2012) 32: 673. doi:10.1007/BF03261921

Abstract

Background: Neural tube defects (NTDs) are congenital malformations that occur during early embryonic development. Suboptimal maternal folate status is a well-known risk factor for the occurrence of NTDs, and periconceptional folic acid supplementation has been shown to reduce the risk of NTDs. Folate-supplemented oral contraceptives (OCs) offer a means of improving folate status in women of childbearing potential by increasing their likelihood of having raised folate levels at the time of conception.

Objective: This study aimed to demonstrate bioequivalence of ethinylestradiol (EE), drospirenone and L-5-methyl-tetrahydrofolate (L-5-methyl-THF; active moiety of levomefolate calcium) when taken as a new folate-supplemented OC containing EE/drospirenone/levomefolate calcium, with the respective OC containing EE/drospirenone and a tablet containing levomefolate calcium only.

Methods: This was a randomized, open-label, three-period crossover study carried out at a single centre in Germany. The study included 45 healthy women (age range 18–38 years). The women were randomly assigned to single doses of (i) EE 0.03 mg/drospirenone 3 mg/levomefolate calcium 0.451 mg (SAFYRAL®), (ii) EE 0.03 mg/drospirenone 3 mg (Yasmin®), and (iii) levomefolate calcium 0.451 mg, administered using a crossover design, with one or more menstrual cycle washout between doses. The primary variables were maximum concentrations (Cmax) and area under the concentration versus time curve (AUC) values for EE, drospirenone and L-5-methyl-THF.

Results: The bioavailability of EE and drospirenone was similar after administration of EE/drospirenone/levomefolate calcium and EE/drospirenone. The geometric mean ratios (GMRs) and its 90% confidence intervals (CIs) for AUC values and Cmax were within the pre-specified range (80.00–125.00%) for bioequivalence for EE and drospirenone in both formulations. The bioavailability of L-5-methyl-THF was similar after administration of EE/drospirenone/levomefolate calcium and levomefolate calcium. The respective GMRs and 90% CIs of baseline-uncorrected and -corrected AUClast (AUC from time zero to time of last measurable concentration) and Cmax were also within the 80.00–125.00% range.

Conclusion: The novel folate-supplemented OC EE/drospirenone/levomefolate calcium is bioequivalent to the established OC Yasmin® (EE/drospirenone components) and to levomefolate calcium (folate component).

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  • Herbert Wiesinger
    • 1
  • Urte Eydeler
    • 2
  • Frank Richard
    • 3
  • Dietmar Trummer
    • 1
  • Hartmut Blode
    • 1
  • Beate Rohde
    • 1
  • Konstanze Diefenbach
    • 1
  1. 1.Bayer HealthCare PharmaceuticalsBerlinGermany
  2. 2.Scope International GmbHHamburgGermany
  3. 3.Nycomed GmbH — A Takeda CompanyKonstanzGermany